Clinical data | |
---|---|
Other names | TAK-906; ATC-1906 |
Drug class | Dopamine antagonist |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
Chemical and physical data | |
Formula | C31H39N3O4 |
Molar mass | 517.670 g·mol−1 |
3D model ( JSmol) | |
| |
|
Trazpiroben (developmental code name TAK-906) is a dopamine antagonist drug which was under development for the treatment of gastroparesis. [1] [2] [3] [4] [5] It acts as a peripherally selective dopamine D2 and D3 receptor antagonist. [1] [2] The drug has been found to strongly increase prolactin levels in humans, similarly to other peripherally selective D2 receptor antagonists like domperidone. [5] Clinical development of trazpiroben was discontinued before April 2022. [1] Trazpiroben was originated by Altos Therapeutics and was under development by Takeda Oncology. [1]
Clinical data | |
---|---|
Other names | TAK-906; ATC-1906 |
Drug class | Dopamine antagonist |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
Chemical and physical data | |
Formula | C31H39N3O4 |
Molar mass | 517.670 g·mol−1 |
3D model ( JSmol) | |
| |
|
Trazpiroben (developmental code name TAK-906) is a dopamine antagonist drug which was under development for the treatment of gastroparesis. [1] [2] [3] [4] [5] It acts as a peripherally selective dopamine D2 and D3 receptor antagonist. [1] [2] The drug has been found to strongly increase prolactin levels in humans, similarly to other peripherally selective D2 receptor antagonists like domperidone. [5] Clinical development of trazpiroben was discontinued before April 2022. [1] Trazpiroben was originated by Altos Therapeutics and was under development by Takeda Oncology. [1]